Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.
about
Exposure to bisphenol A correlates with early-onset prostate cancer and promotes centrosome amplification and anchorage-independent growth in vitroTreatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.NaPLK-1 Targeted Inhibitors and Their Potential against TumorigenesisThe Plk1 inhibitor BI 2536 temporarily arrests primary cardiac fibroblasts in mitosis and generates aneuploidy in vitroStructural basis for the inhibition of Polo-like kinase 1PLK1, A Potential Target for Cancer TherapyA series of beta-carboline derivatives inhibit the kinase activity of PLKsUnliganded progesterone receptors attenuate taxane-induced breast cancer cell death by modulating the spindle assembly checkpointA randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative netwThe Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study.Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activityA phase I study of volasertib combined with afatinib, in advanced solid tumors.Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors.Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.Association of p21 with NF-YA suppresses the expression of Polo-like kinase 1 and prevents mitotic death in response to DNA damage.Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitorsMolecular stratification of early breast cancer identifies drug targets to drive stratified medicineThe σ2 receptor: a novel protein for the imaging and treatment of cancer.Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.SmSak, the second Polo-like kinase of the helminth parasite Schistosoma mansoni: conserved and unexpected roles in meiosisA novel anti-tumor inhibitor identified by virtual screen with PLK1 structure and zebrafish assay.GSK-3 modulates cellular responses to a broad spectrum of kinase inhibitorsKinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo.Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinomaThe oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressorPhase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours.Centrosomal protein 55 (Cep55) stability is negatively regulated by p53 protein through Polo-like kinase 1 (Plk1)PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.The APC/C Ubiquitin Ligase: From Cell Biology to TumorigenesisRNA-Seq reveals common and unique PXR- and CAR-target gene signatures in the mouse liver transcriptome.Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.Loss of KLF14 triggers centrosome amplification and tumorigenesis.Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma.Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia.Novel compounds in the treatment of lung cancer: current and developing therapeutic agents.Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma.Modulating polo-like kinase 1 as a means for cancer chemoprevention
P2860
Q21132302-C4F3AE77-738F-467C-8635-4D32DE0326BDQ24597616-D93DAD7A-FF4C-4D12-9083-82EAE37DCFB0Q26777811-BA1383DD-088E-45A5-9963-4EF053DB0FA7Q27319063-14D7A744-29A5-44DD-9C16-07E8BE44EDFFQ27685281-E388ABED-1252-44CF-A339-641E18373741Q28078772-BF230A62-9EE3-4E82-8DA4-88C937AF5D6DQ28484219-82AA5498-B6D9-40F1-92BD-592BE2B47D4AQ30560953-5A0AE91B-C550-455F-B7FD-0AB38C0847F5Q33401811-DE60070E-0CED-456B-A834-76D99B277EDCQ33403311-DD5C2FF1-FAE6-41E6-BA84-AF6C04D1419DQ33421343-F84BE8D1-4F12-4A0C-96DB-D711044420C6Q33425698-D795181A-3B4D-40CF-8EF1-A4C0C0B294C0Q33428061-6CAD7965-5FB5-4CE1-9159-7B985C1FE813Q33443830-3AF21B0B-9095-4898-905E-440D76A7A6B4Q33577628-4AD392E3-BF16-40E6-9ACD-B30E15F0AD5DQ33695146-0BE02910-5B37-49C0-98D8-5AB06411E850Q33713695-57AF9272-A92E-4D1B-BDB5-496676978A61Q33731350-188A7900-6372-4EB0-8057-4CFA801A8031Q33782364-D684FC71-6E03-42AF-A752-2A1DE9CD5489Q34106830-3D4A7945-B3F1-40B8-9319-EC0B49F41D31Q34328607-BC02FD8C-B106-43B9-9585-BA8789E7BA72Q34711921-E5D59451-2D5C-4FC8-9302-1D5BE2B16FF7Q34735363-F9E024CD-DE09-4CD9-B73D-31293E069E2AQ34979448-8ADB4094-2993-43FD-BA12-0B745E21B9C2Q35235743-B4606E3A-F733-4C36-9F92-26EE1A45981BQ35560770-38A08515-1839-4A67-95E9-2C3994A29E75Q35592084-23D14C73-E47D-49CB-8E2F-CD6C24DCB49EQ35703610-A1F4F22D-73D7-4B77-AF44-9ACD2236F7A5Q35763224-D11A1FBB-94DA-4624-A59A-4FEE9488EF3CQ35832219-0A036363-E923-4D41-B2CA-E1B46D299907Q35971862-FE6DE80A-51DC-49BE-84C3-CC0AFB6C754CQ35998854-9AAB11BE-6E3C-4E6B-97DC-CFF440334A88Q36062154-995F4F65-EDDC-4313-B978-4A55DD7F9379Q36145942-2E24DC61-8AD7-4E4E-A2F7-C1849D7A3F7FQ36452688-CE1A1481-2BD2-4391-AAFC-97FD90431882Q36467485-493D06A8-CC8F-4317-B3A1-3739823A1A22Q36890658-9FA13C50-1EDD-4DCB-B556-08AC850D0A5BQ37059611-F4C02838-05F1-4C2D-8654-BC86DBA57D93Q37262757-EE75FD5E-05BC-4073-96C1-65D2B269789AQ37682665-253F274E-D7BE-42F4-A679-BCB5B71183F9
P2860
Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Polo-like kinase (PLK) inhibit ...... nical development in oncology.
@en
Polo-like kinase
@nl
type
label
Polo-like kinase (PLK) inhibit ...... nical development in oncology.
@en
Polo-like kinase
@nl
prefLabel
Polo-like kinase (PLK) inhibit ...... nical development in oncology.
@en
Polo-like kinase
@nl
P1433
P1476
Polo-like kinase (PLK) inhibit ...... nical development in oncology.
@en
P304
P356
10.1634/THEONCOLOGIST.2009-0010
P577
2009-05-27T00:00:00Z